HSCT is widely used for hematopoietic and non‐hematopoietic diseases treatment clinically, but limited by the number of therapeutic HSPCs.[3, 45, 46] Large‐scale ex vivo expansion of HSPCs still remains in the preclinical trial stage currently.[47, 48] Our previous study reported that implantation of a BMP‐2‐loaded gelatin scaffold induced an in vivo osteo‐organoid with native bone marrow‐like architecture by activating the residual regenerative capacity of mammals.[19] This approach holds promise for providing therapeutic HSPCs. The gene discussed is BMP2; the disease is hematologic disorder.